Traws Pharma, Inc. (NASDAQ:TRAW) Short Interest Update

Traws Pharma, Inc. (NASDAQ:TRAW) was the target of a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 270,200 shares, a growth of 79.2% from the January 31st total of 150,800 shares. Currently, 10.2% of the shares of the company are sold short. Based on an average daily volume of 540,300 shares, the days-to-cover ratio is currently 0.5 days.

Hedge Funds Weigh In On Traws Pharma

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Millennium Management LLC bought a new position in Traws Pharma in the 4th quarter worth approximately $89,000. Renaissance Technologies LLC bought a new position in Traws Pharma in the 4th quarter worth approximately $89,000. Geode Capital Management LLC bought a new position in Traws Pharma in the 4th quarter worth approximately $185,000. Boothbay Fund Management LLC bought a new position in Traws Pharma in the 4th quarter worth approximately $252,000. Finally, Vestal Point Capital LP bought a new position in Traws Pharma in the 4th quarter worth approximately $666,000. 7.95% of the stock is owned by institutional investors.

Traws Pharma Price Performance

Shares of TRAW stock opened at $2.29 on Tuesday. Traws Pharma has a 12-month low of $2.24 and a 12-month high of $27.50. The company has a market cap of $8.36 million, a price-to-earnings ratio of -0.02 and a beta of 1.10. The business has a 50 day simple moving average of $7.06.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.